[{"data":1,"prerenderedAt":75},["ShallowReactive",2],{"story-6080-cn":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":15,"questions":16,"relatedArticles":26,"body_color":73,"card_color":74},"6080",null,"基因疗法突破性进展改变肌萎缩侧索硬化症治疗格局","靶向分子干预开启神经系统疾病管理新前沿",[],[10,11,12,13,14],"https://medicine.washu.edu/app/uploads/2025/12/251010_ALS_Rickey_home_05191-700x467.jpg","https://s.abcnews.com/images/Health/wheelchair-gty-jef-251222_1766418219921_hpMain_16x9_1600.jpg","https://medicine.washu.edu/app/uploads/2025/12/250916_ALS_tre_photos_03923-2-700x467.jpg","https://s.abcnews.com/images/GMA/250617_gma_sawyer2_hpMain_16x9_608.jpg","https://res.cloudinary.com/broadcastmed/image/fetch/q_auto,c_fill,g_faces:center,f_auto,h_628,w_1280/https://conexiant.com/media/1ximwnwh/als.jpg","**托夫森**，一种用于 SOD1 相关 ALS 的开创性基因疗法的出现，标志着神经系统治疗的一个关键时刻，挑战了长期以来对进行性神经退行性疾病的假设。这种创新方法展示了**精准医学**如何从根本上重塑我们对看似难以治愈的疾病的理解。\n\n**靶向基因干预** 产生了前所未有的临床结果，QALSODY 研究揭示了引人注目的患者改善，这些改善以前被认为是不可思议的。这项研究跟踪了 108 名参与者，早期组中有 27 位参与者在三年内经历了肌肉力量的改善——这种现象挑战了传统的 ALS 进展模型。\n\n该疗法的潜力通过其重要的临床指标得到强调：接受托夫森治疗的患者在六个月内的死亡风险降低了 48%，并且神经丝（一种关键的神经退行性标志物）持续减少。这不仅仅是渐进性的进展；它代表了一种潜在的范式转变，即将 ALS 从终末诊断转变为将其概念化为一种可控制的慢性疾病。\n\n更广泛的影响超出了直接的患者群体。在美国大约有 34,000 例 ALS 病例，预计到 2030 年将增长到超过 36,000 例，**QALSODY** 展示了未来的一瞥，在那里，靶向基因疗法可以从根本上改变疾病轨迹。该药物在美国的加速批准和在全球 44 个国家的授权标志着对其变革潜力的日益认可。\n\n至关重要的是，这项突破证明了**精准医学**的力量——靶向特定的基因突变（在这种情况下，影响 2% 的 ALS 患者的 SOD1 突变）以开发高度专业的治疗方法。这种方法预示着未来医疗干预将变得越来越个性化，从千篇一律的治疗方法转向分子靶向解决方案。",[17,20,23],{"title":18,"answer":19,"author":5,"avatar":5,"time":5},"托夫森与之前的 ALS 疗法有何不同？","与以往仅控制症状的治疗方法不同，托夫森是一种靶向基因干预，直接针对SOD1基因突变。它通过减少导致肌肉退化的蛋白质产生，可能减缓甚至部分逆转疾病进展。",{"title":21,"answer":22,"author":5,"avatar":5,"time":5},"有多少比例的ALS患者能从这种治疗中获益？","目前，tofersen 针对大约 2% 患有特定 SOD1 基因突变的 ALS 患者。然而，这项突破证明了精准医学的概念验证，这可能激发针对其他神经系统疾病的基因变异采取类似的靶向方法。",{"title":24,"answer":25,"author":5,"avatar":5,"time":5},"QALSODY 研究最重要的临床结果是什么？","研究表明，研究结果引人注目，包括在六个月内死亡风险降低了48%，27名参与者在三年内肌肉力量有所提高，以及神经丝——一个关键的神经退行性变指标——持续下降。这些结果挑战了此前对肌萎缩侧索硬化症（ALS）不可逆转地进展的认识。",[27,32,37,41,45,49,53,57,61,65,69],{"id":28,"title":29,"source":30,"logo":5,"time":31},134326,"The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why","https://finance.yahoo.com/news/bull-case-biogen-biib-could-031246547.html","2天前",{"id":33,"title":34,"source":35,"logo":11,"time":36},134327,"New drug may slow progression of ALS in small group of patients: Study","https://abcnews.go.com/Health/new-drug-slow-progression-als-small-group-patients/story?id=128615578","3天前",{"id":38,"title":39,"source":40,"logo":5,"time":36},134328,"The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS","https://investors.biogen.com/news-releases/news-release-details/journal-american-medical-association-jama-neurology-publishes",{"id":42,"title":43,"source":44,"logo":5,"time":36},134284,"Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment","https://www.gurufocus.com/news/4080100/biogen-biib-phase-3-study-highlights-benefits-of-qalsody-in-als-treatment",{"id":46,"title":47,"source":48,"logo":5,"time":36},134285,"Biogen’s QALSODY shows sustained benefits for SOD1-ALS patients","https://www.investing.com/news/company-news/biogens-qalsody-shows-sustained-benefits-for-sod1als-patients-93CH-4419809",{"id":50,"title":51,"source":52,"logo":5,"time":36},134286,"Some ALS patients regained lost function in long-term QALSODY study","https://www.stocktitan.net/news/BIIB/the-journal-of-the-american-medical-association-jama-neurology-349vcao1nszs.html",{"id":54,"title":55,"source":56,"logo":10,"time":36},134287,"New ALS drug stabilizes decline with a trend toward improved strength, mobility for some","https://medicine.washu.edu/news/new-als-drug-stabilizes-decline-with-trend-toward-improved-strength-mobility-for-some/",{"id":58,"title":59,"source":60,"logo":14,"time":36},134329,"Long-Term Tofersen Shows Benefit in SOD1-Mutated ALS","https://conexiant.com/neurology/articles/long-term-tofersen-shows-benefit-in-sod1-mutated-als/",{"id":62,"title":63,"source":64,"logo":12,"time":36},134281,"Still standing: Inside a new era of ALS treatment","https://medicine.washu.edu/impact/neurosciences/als/",{"id":66,"title":67,"source":68,"logo":13,"time":36},134282,"Small subset of ALS patients see improvement with new drug, study finds","https://www.goodmorningamerica.com/wellness/story/new-drug-slow-progression-als-small-group-patients-128615578",{"id":70,"title":71,"source":72,"logo":5,"time":36},134283,"Biogen announces publication of long term results from Phase 3 VALOR study","https://www.tipranks.com/news/the-fly/biogen-announces-publication-of-long-term-results-from-phase-3-valor-study-thefly","#6e739cff","#6e739c4d",1766681651168]